|Table of Contents|

Research advances of cuproptosis and copper complexes in antitumor therapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 18
Page:
3502-3507
Research Field:
Publishing date:

Info

Title:
Research advances of cuproptosis and copper complexes in antitumor therapy
Author(s):
LIU Wei1; ZHANG Yangqiurong1; LI Li1; CAO Junyu1; CHEN Xihua2; YANG Kunxian1
1.Department of Breast and Thyroid Surgery,the First People's Hospital of Yunnan Province,Yunnan Kunming 650034,China;2.Department of General Surgery,the People's Hospital of Mouding County,Yunnan Chuxiong 675500,China.
Keywords:
cuproptosis; copper complexes; copper homeostasis; cell death; antitumor therapy
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2023.18.032
Abstract:
Copper (Cu) is critical for various physiological processes,and copper homeostasis is tightly regulated to limit oxidative stress production and toxicity.Elevated Cu content in serum and tumor tissues is correlated with tumorigenesis，cancer progression and metastasis.Hence,targeting copper therapy has emerged as a new strategy in antitumor therapy.Cuproptosis is a novel,distinct from all other known regulatory cell death (RCD),copper-dependent cell death modality,which provides a novel perspective for the connection between copper homeostasis and mitochondrial metabolism.This article reviews the research progress of cuproptosis and copper complexes in antitumor therapy.

References:

[1]RUIZ LM,LIBEDINSKY A,ELORZA AA.Role of copper on mitochondrial function and metabolism［J］.Front Mol Biosci,2021,8:711227.
[2]LI Y.Copper homeostasis:Emerging target for cancer treatment［J］.IUBMB Life,2020,72(9):1900-1908.
[3]GE EJ,BUSH AI,CASINI A,et al.Connecting copper and cancer:from transition metal signalling to metalloplasia［J］.Nat Rev Cancer,2022,22(2):102-113.
[4]LI SR,BU LL,CAI L.Cuproptosis:lipoylated TCA cycle proteins-mediated novel cell death pathway［J］.Signal Transduct Target Ther,2022,7(1):158.
[5]TSVETKOV P,DETAPPE A,CAI K,et al.Mitochondrial metabolism promotes adaptation to proteotoxic stress［J］.Nat Chem Biol,2019,15(7):681-689.
[6]TSVETKOV P,COY S,PETROVA B,et al.Copper induces cell death by targeting lipoylated TCA cycle proteins［J］.Science,2022,18(6586):1254-1261.
[7]BABAK MV,AHN D.Mdulation of intracellular copper levels as the mechanism of action of anticancer copper complexes:clinical relevance［J］.Biomedicines,2021,9(8):852.
[8]MICHNIEWICZ F,SALETTA F,ROUAEN JRC,et al.Copper:an intracellular achilles' heel allowing the targeting of epigenetics,kinase pathways,and cell metabolism in cancer therapeutics［J］.Chem Med Chem,2021,16(15):2315-2329.
[9]TSANG T,POSIMO JM,GUDIEL AA,et al.Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma［J］.Nat Cell Biol,2020,22(4):412-424.
[10]PHILLIPS AMF,POMBEIRO AJL.Transition metal-based prodrugs for anticancer drug delivery［J］.Curr Med Chem,2019,26(41):7476-7519.
[11]BREWER GJ,HEDERA P,KLUIN KJ,et al.Treatment of Wilson disease with ammonium tetrathiomolybdate:III.Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy［J］.Arch Neurol,2003,60(3):379-385.
[12]ZHENG P,ZHOU C,LU L,et al.Elesclomol:a copper ionophore targeting mitochondrial metabolism for cancer therapy［J］.J Exp Clin Cancer Res,2022,41(1):271.
[13]O' DAY SJ,EGGERMONT AMM,CHIARION-SILENI V,et al.Final results of phase III SYMMETRY study:randomized,double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma［J］.J Clin Oncol,2013,31(9):1211-1218.
[14]TAWARI PE,WANG Z,NAJLAH M,et al.The cytotoxic mechanisms of disulfiram and copper(II) in cancer cells［J］.Toxicol Res (Camb),2015,4(6):1439-1442.
[15]DENOYER D,CLATWORTHY SA,CATER MA.Copper complexes in cancer therapy［J］.Met Ions Life Sci,2018,18:469-506.
[16]CHAN N,WILLIS A,KORNHAUSER N,et al.Influencing the tumor microenvironment:a phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases［J］.Clin Cancer Res,2017,23(3):666-676.
[17]RYUMON S,OKUI T,KUNISADA Y,et al.Ammonium tetrathiomolybdate enhances the antitumor effect of cisplatin via the suppression of ATPase copper transporting beta in head and neck squamous cell carcinoma［J］.Oncol Rep,2019,42(6):2611-2621.
[18]ISHIDA S,MCCORMICK F,SMITH-MCCUNE K,et al.Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator［J］.Cancer Cell,2010,17(6):574-583.
[19]KUO MT,HUANG YF,CHOU CY,et al.Targeting the copper transport system to improve treatment efficacies of platinum-containing drugs in cancer chemotherapy［J］.Pharmaceuticals (Basel),2021,14(6):549.
[20]ARNESANO F,NATILE G.Interference between copper transport systems and platinum drugs［J］.Semin Cancer Biol,2021,76:173-188.
[21]CUI H,ZHANG AJ,MCKEAGE MJ,et al.Copper transporter 1 in human colorectal cancer cell lines:Effects of endogenous and modified expression on oxaliplatin cytotoxicity［J］.J Inorg Biochem,2017,177:249-258.
[22]FANG T,CHEN W,SHENG Y,et al.Tetrathiomolybdate induces dimerization of the metal-binding domain of ATPase and inhibits platination of the protein［J］.Nat Commun,2019,10(1):186.
[23]JIANG YC,HUO ZY,QI XL,et al.Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes［J］.Nanomedicine 2022,17(5):303-324.
[24]KADU P,SAWANT B,KALE PP,et al.Copper-lowering agents as an adjuvant in chemotherapy［J］.Indian J Pharmacol,2021,53(3):221-225.
[25]SUN T,ZHANG G,GUO Z,et al.Co-delivery of Cu(I) chelator and chemotherapeutics as a new strategy for tumor theranostic［J］.J Control Release,2020,321:483-496.
[26]RAMCHANDANI D,BERISA M,TAVAREZ DA,et al.Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis［J］.Nat Commun,2021,12(1):7311.
[27]GUO YJ,PAN WW,LIU SB,et al.ERK/MAPK signalling pathway and tumorigenesis［J］.Exp Ther Med,2020,19(3):1997-2007.
[28]BRADY DC,CROWE MS,TURSKI ML,et al.Copper is required for oncogenic BRAF signalling and tumorigenesis［J］.Nature,2014,509(7501):492-496.
[29]SAMMONS S,BRADY D,VAHDAT L,et al.Copper suppression as cancer therapy:the rationale for copper chelating agents in BRAFV600 mutated melanoma［J］.Melanoma Manag,2016,3(3):207-216.
[30]WU Z,ZHAG W,KANG YJ.Copper affects the binding of HIF-1alpha to the critical motifs of its target genes［J］.Metallomics,2019,11(2):429-438.
[31]PAN Q,KLEER CG,GOLEN KLV,et al.Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis［J］.Cancer Res,2002,62(17):4854-4859.
[32]FENG W,YE F,XUE W,et al.Copper regulation of hypoxia-inducible factor-1 activity［J］.Mol Pharmacol,2009,75(1):174-182.
[33]QASEM Z,PAVLIN M,RITACCO I,et al.Disrupting Cu trafficking as a potential therapy for cancer［J］.Front Mol Biosci,2022,9:1011294.
[34]DONATE F,JUAREZ JC,BURNETT ME,et al.Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224)［J］.Br J Cancer,2008,98(4):776-783.
[35]BLOCKHUYS S,ZHANG X,WITTUNG-STAFSHEDE P.Single-cell tracking demonstrates copper chaperone Atox1 to be required for breast cancer cell migration［J］.Proc Natl Acad Sci USA,2020,117(4):2014-2019.
[36]WANG J,LUO C,SHAN C,et al.Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation［J］.Nat Chem,2015,7(12):968-979.
[37]DE SOUSA LINHARES A,BATTIN C,JUTZ S,et al.Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling［J］.Sci Rep,2019,9(1):11472.
[38]VOLI F,VALLI E,LERRA L,et al.Intra-tumoral copper modulates PD-L1 expression and influences tumor immune evasion［J］.Cancer Res,2020,80(19):4129-4144.
[39]庞敬瑶,李佩玲,AFERIN B,等.基于铁死亡的癌症治疗新策略［J］.现代肿瘤医学,2021,29(06):1058-1061. PANG JY，LI PL，AFERIN B，et al.New strategies of cancer therapy based on ferroptosi［J］.Modern Oncology，2021,29(06):1058-1061.
[40]ZHONG X,DAI X,WANG Y,et al.Copper-based nanomaterials for cancer theranostics［J］.Wiley Interdiscip Rev Nanomed Nanobiotechnol,2022,14(4):e1797.
[41]ZHANG H,SONG F,DONG C,et al.Co-delivery of nanoparticle and molecular drug by hollow mesoporous organosilica for tumor-activated and photothermal-augmented chemotherapy of breast cancer［J］.J Nanobiotechnology,2021,19(1):290.
[42]CHEN Q,ZHENG Z,HE X,et al.A tumor-targeted theranostic nanomedicine with strong absorption in the NIR-II biowindow for image-guided multi-gradient therapy［J］.J Mater Chem B,2020,8(41):9492-9501.
[43]LIU C,CHEN Y,ZHAO J,et al.Self-assembly of copper-DNAzyme nanohybrids for dual-catalytic tumor therapy［J］.Angew Chem Int Ed Engl,2021,60(26):14324-14328.
[44]CUI L,GOUW AM,LAGORY EL,et al.Mitochondrial copper depletion suppresses triple-negative breast cancer in mice［J］.Nat Biotechnol,2021,39(3):357-367.
[45]YANG Y,TANG J,ZHANG M,et al.Responsively aggregatable sub-6 nm nanochelators induce simultaneous antiangiogenesis and vascular obstruction for enhanced tumor vasculature targeted therapy［J］.Nano Lett,2019,19(11):7750-7759.
[46]XU Y,LIU SY,ZENG L,et al.Enzyme-engineered nonporous copper(I) coordination polymer nanoplatform for cuproptosis-based synergistic cancer therapy［J］.Adv Mater,2022,34(43):e2204733.
[47]CHANG X,ZHU M,TANG X,et al.Enhanced manipulation of tumor microenvironments by nanomotor for synergistic therapy of malignant tumor［J］.Biomaterials,2022,290:121853.
[48]TSYNBAL S,LI G,AGADZHANIAN N,et al.Recent advances in copper-based organic complexes and nanoparticles for tumor theranostics［J］.Molecules,2022,27(20):7066.
[49]CHEN L,MIN J,WANG F.Copper homeostasis and cuproptosis in health and disease［J］.Signal Transduct Target Ther,2022,7(1):378.

Memo

Memo:
National Natural Science Foundation of China(No.82002812）；国家自然科学基金青年项目（编号：82002812）；昆明医科大学应用基础研究联合专项(编号：202101AY070001-239）
Last Update: 1900-01-01